TY - JOUR
T1 - Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents
AU - Vaxman, Iuliana
AU - Visram, Alissa
AU - Kumar, Shaji
AU - Dispenzieri, Angela
AU - Buadi, Francis
AU - Dingli, David
AU - Lacy, Martha
AU - Muchtar, Eli
AU - Kapoor, Prashant
AU - Hogan, William
AU - Hayman, Suzanne
AU - Leung, Nelson
AU - Gonsalves, Wilson
AU - Kourelis, Taxiarchis
AU - Warsame, Rahma
AU - Berger, Tamar
AU - Gertz, Morie A.
N1 - Funding Information:
Funding Grant Funding Amyloidosis Foundation; International Wal-denstom Foundation. NCI SPORE MM SPORE 5P50 CA186781-04.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/5
Y1 - 2021/5
N2 - Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Median time from diagnosis to ASCT was 6.85 months (IQR 5.2–10.52) and 50%. received reduced intensity conditioning with melphalan 140 mg/m2. 48% of patients completed the ASCT without requiring hospitalization and 52% (n = 26) of patients required hospitalization with a median duration of hospital admission of 9 days (IQR 5–13). Reasons for hospitalization included fever or infection (32%), cardiac arrhythmia (36%), and dehydration (32%). Overall response rate was 100% with a complete response seen in 57% of patients. Median overall survival and progression free survival for the cohort were 82 months and 33 months, respectively. One patient died within 100 days of transplant representing a 2% 100-day mortality rate. ASCT is safe and efficacious in carefully selected MM patients aged 75 or above and we believe that age should not be an exclusion factor for ASCT in MM.
AB - Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Median time from diagnosis to ASCT was 6.85 months (IQR 5.2–10.52) and 50%. received reduced intensity conditioning with melphalan 140 mg/m2. 48% of patients completed the ASCT without requiring hospitalization and 52% (n = 26) of patients required hospitalization with a median duration of hospital admission of 9 days (IQR 5–13). Reasons for hospitalization included fever or infection (32%), cardiac arrhythmia (36%), and dehydration (32%). Overall response rate was 100% with a complete response seen in 57% of patients. Median overall survival and progression free survival for the cohort were 82 months and 33 months, respectively. One patient died within 100 days of transplant representing a 2% 100-day mortality rate. ASCT is safe and efficacious in carefully selected MM patients aged 75 or above and we believe that age should not be an exclusion factor for ASCT in MM.
UR - http://www.scopus.com/inward/record.url?scp=85097150050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097150050&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-01159-9
DO - 10.1038/s41409-020-01159-9
M3 - Article
C2 - 33273658
AN - SCOPUS:85097150050
SN - 0268-3369
VL - 56
SP - 1144
EP - 1150
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -